[Accepted Manuscript] Disease characteristics and treatment of patients with diabetes mellitus attending government health services in Indonesia, Peru, Romania and South Africa

To describe the characteristics and management of Diabetes mellitus (DM) patients from low- and middle-income countries (LMIC). We systematically characterized consecutive DM patients attending public health services in urban settings in Indonesia, Peru, Romania and South Africa, collecting data on...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Soetedjo, N.N.M, McAllister, S.M, Ugarte-Gil, C, Firanescu, A.G, Ronacher, K, Alisjahbana, B, Costache, A.L, Zubiate, C, Malherbe, S.T, Koesoemadinata, R.C, Laurence, Y.V, Pearson, F, Kerry-Barnard, S, Ruslami, R, Moore, D.A.J, Ioana, M, Kleynhans, L, Pernama, H, Hill, P.C, Mota, M, Walzl, G, Dockrell, H.M, Critchley, J.A, van Crevel, R, TANDEM consortium (members listed in full in Supplementary File)
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To describe the characteristics and management of Diabetes mellitus (DM) patients from low- and middle-income countries (LMIC). We systematically characterized consecutive DM patients attending public health services in urban settings in Indonesia, Peru, Romania and South Africa, collecting data on DM treatment history, complications, drug treatment, obesity, HbA1c, and cardiovascular risk profile; and assessing treatment gaps against relevant national guidelines. Patients (median 59 years, 62.9% female) mostly had type 2 diabetes (96%), half for >5 years (48.6%). Obesity (45.5%) and central obesity (females 84.8%; males 62.7%) were common. The median HbA1c was 8.7% (72 mmol/mol), ranging from 7.7% (61 mmol/mol; Peru) to 10.4% (90 mmol/mol; South Africa). Antidiabetes treatment included metformin (62.6%), insulin (37.8%), and other oral glucose-lowering drugs (34.8%). Disease complications included eyesight problems (50.4%), EGFR
ISSN:1360-2276
DOI:10.1111/tmi.13137